David F. Penson
Vanderbilt University Medical Center
609 Papers
3.3K Citations
David F. Penson is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 70, co-authored 570 publications. Previous affiliations of David F. Penson include UCLA Medical Center & American Society of Clinical Oncology.
Chat about Author
Papers
Diffusion of surgical innovation among patients with kidney cancer
TL;DR: For both outcomes, the percentage of total variance attributable to surgeon factors was consistently higher than that attributable to patient characteristics, and dismantling barriers to surgeon adoption of partial nephrectomy and laparoscopy is an important step toward improving the quality of care for patients with early-stage kidney cancer.
26
Racial variation in the incidence of squamous cell carcinoma of the bladder in the United States.
TL;DR: Squamous cell carcinoma of the bladder appears to be twice as common in black as in white individuals in the United States.
26
The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer
TL;DR: This review summarizes the existing comparative effectiveness evidence of treatments for localized prostate cancer with an emphasis on oncologic control and provides a review of emerging therapies such as cryotherapy and high-intensity frequency ultrasound.
25
Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study
Huei-Ting Tsai,Ruth M. Pfeiffer,George K. Philips,Ana Barac,Alex Z. Fu,David F. Penson,Yingjun Zhou,Arnold L. Potosky +7 more
TL;DR: Intermittent androgen deprivation therapy was associated with a lower risk of heart failure and fracture compared to continuous androgens deprivation therapy, which raises toxicity concerns for continuous relative to intermittent therapy and suggests that intermittent androgen deprived therapy may represent a safer therapeutic choice in elderly men with advanced prostate cancer.
24